Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040)

被引：0
作者：
Tomoya Fukui
Jiichiro Sasaki
Satoshi Igawa
Akiko Kada
Toshiki I. Saito
Yoshihito Kogure
Hiroaki Okamoto
Katsuhiko Naoki
机构：
[1] Kitasato University School of Medicine,Department of Respiratory Medicine
[2] Kitasato University School of Medicine,Research and Development Center for New Medical Frontiers
[3] National Hospital Organization Nagoya Medical Center,Clinical Research Center
[4] National Hospital Organization Nagoya Medical Center,Department of Respiratory Medicine
[5] Yokohama Municipal Citizen’s Hospital,Department of Respiratory Medicine and Medical Oncology
来源：
BMC Cancer | / 22卷
关键词：
Osimertinib; Epidermal growth factor receptor; Non-small cell lung cancer; Poor performance status; First-line chemotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 107 条
[1]  
Lynch TJ(2004)Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2129-2139
[2]  
Bell DW(2004)EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science. 304 1497-1500
[3]  
Sordella R(2009)Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 947-957
[4]  
Gurubhagavatula S(2016)Not all epidermal growth factor receptor mutations in lung cancer are created equal: perspectives for individualized treatment strategy Cancer Sci 107 1179-1186
[5]  
Okimoto RA(2016)Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers Oncotarget. 7 23874-23884
[6]  
Brannigan BW(2015)AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer N Engl J Med 372 1689-1699
[7]  
Paez JG(2014)AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer Cancer Discov 4 1046-1061
[8]  
Jänne PA(2018)Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer N Engl J Med 378 113-125
[9]  
Lee JC(2019)Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset Jpn J Clin Oncol 49 29-36
[10]  
Tracy S(1991)Survival determinants in extensive-stage non-small-cell lung cancer: the southwest oncology group experience J Clin Oncol 9 1618-1626
12345678910